Upregulation of α-synuclein expression in the rat cerebellum in experimental hepatic encephalopathy

I. Suárez, G. Bodega and B. Fernández (2010) Neuropathology and Applied Neurobiology36, 422–435
Upregulation of α‐synuclein expression in the rat cerebellum in experimental hepatic encephalopathy Aims: The overexpression of α‐synuclein has been associated with neurodegenerative diseases, especially...

Full description

Saved in:
Bibliographic Details
Published inNeuropathology and applied neurobiology Vol. 36; no. 5; pp. 422 - 435
Main Authors Suárez, I., Bodega, G., Fernández, B.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.08.2010
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:I. Suárez, G. Bodega and B. Fernández (2010) Neuropathology and Applied Neurobiology36, 422–435
Upregulation of α‐synuclein expression in the rat cerebellum in experimental hepatic encephalopathy Aims: The overexpression of α‐synuclein has been associated with neurodegenerative diseases, especially when the protein aggregates to form insoluble structures. The present study examined the effect of chronic hyperammonaemia on α‐synuclein expression in the rat cerebellum following portacaval anastomosis (PCA). Methods: Immunohistochemical and western blot determinations were performed 1 month and 6 months after the PCA procedure. Results: A time‐dependent increase in α‐synuclein expression was seen in the cerebellar grey matter compared with the controls. At 1 month post PCA, α‐synuclein‐immunopositive material was observed in the molecular layer, while the Purkinje cells showed weak α‐synuclein expression, and α‐synuclein aggregates were observed throughout the granular layer. At 6 months post PCA, α‐synuclein expression was significantly increased compared with the controls. α‐synuclein‐immunostained astroglial cells were also found; the Bergmann glial cells showed α‐synuclein‐positive processes in the molecular layer of PCA‐exposed rats, and in the granular layer, perivascular astrocytes showed intense α‐synuclein immunoreactivity, as indicated by colocalization of α‐synuclein with glial fibrillary acidic protein (GFAP). In addition, ubiquitin‐immunoreactive inclusions were present in PCA‐exposed rats, although they did not colocalize with α‐synuclein. Western blotting performed at 6 months post PCA showed a reduction in the level of soluble α‐synuclein compared with 1 month post PCA and the controls; this reduction was concomitant with an increase in the insoluble form of α‐synuclein. Conclusions: Although the precise mechanism by which α‐synuclein aggregates in PCA‐treated rats remains unknown, the present data suggest an important role for this protein in the onset and progression of hepatic encephalopathy, probably via its expression in astroglial cells.
Bibliography:ark:/67375/WNG-7LTTNN29-L
istex:7FDF9353C32DD8E2378477209D58443BC6A16367
ArticleID:NAN1083
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0305-1846
1365-2990
DOI:10.1111/j.1365-2990.2010.01083.x